If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Medical Affairs » Medical Science Liaison
Download FREE Excerpt
11 Info Graphics
14 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Concerns about compliance and legal limitations are forcing companies to re-examine how they utilize Medical Science Liasons (MSLs). For many companies under a Corporate Integrity Agreement, there is a greater perceived risk over the next few years when it comes to everything from regulatory bodies to changing industry standards.
Best Practices, LLC conducted this study to the provide information on how the roles of MSLs are evolving in the changing pharmaceutical environment and how regulatory concerns are affecting the MSL landscape. This research presents benchmarks around risk factors influencing MSL services in the future, different changes companies are making to MSL policies based on their risk aversion, and the level of support MSLs provide government and advocacy groups. Biopharmaceutical and medical device executives can use this study to determine the best practices for facing the upcoming industry challenges.
Note: Data are presented in two segments: The total benchmark class and a U.S. only segment.
Biotech; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care
Advanced Biohealing; Allergan; Amylin; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Scientific; Cephalon; EndoPharma; Eisai; Gambro; G.E. Healthcare; Genetech; GlaxoSmithKline; Ironwood Pharma; Kadmon Pharma; Laboratorios Esteve; Lantheus Medical Imaging; Metronic; Merck Sharp and Dohme; Novartis; Novo Nordisk; Onyx Pharma; Pfizer; QLT; Quidel; Shire; Takeda; Theravance; UCB
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.